Skip to main content

Table 1 Clinical and demographic information

From: Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease

  

Diagnostic Groups

N

Age

Gender

Aß42/40 ratiod

pTau181

tTau

NfL

GFAP

Mean (SD)

Range

Females N (%)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Cohort I

AD

AD MCI

18

71.4 (6.5)

59–84

9 (50%)

0.044 (0.010)

95.4 (38.5)

460 (120)

1224 (697)

19,811 (7348)

AD dementia

19

70.3 (9.5)

56–84

7 (37%)

0.048 (0.010)

93.3 (40.7)

428 (153)

1422 (483)

19,489 (6319)

NeuroDegen

Frontotemporal dementia (FTD)

18

65.7 (8.2)

51–79

7 (39%)

0.080 (0.015)

32.4 (17.0)

236 (95)

2408 (2648)

17,207 (6923)

Lewy body dementia (LBD/Park)

14

71.6 (11.2)

48–88

4 (29%)

0.081 (0.019)

31.1 (16.6)

227 (105)

2292 (3449)

18,005 (6510)

Motor neuron disease (MND)

6

55.7 (11.1)

40–65

3 (50%)

0.083 (0.011)

26.4 (9.4)

179 (76)

6046 (8140)

9864 (6463)

Dementia NOS

12

75.5 (8.3)

58–89

8 (67%)

0.097 (0.017)

21.7 (8.8)

187 (114)

1733 (1356)

20,663 (14,610)

MCI NOS

12

73.3 (8.6)

60–86

3 (75%)

0.080 (0.012)

27.5 (9.2)

232 (82)

1466 (1444)

19,176 (8624)

NeuroCtrl

Immune/demyelinating diseases (INFL)a

20

47.5 (12.8)

24–69

9 (45%)

0.082 (0.011)

30.7 (33.1)

283 (224)

3829 (7812)

11,337 (6400)

Idiopathic intracranial hypertension (IIH)

20

43.3 (12.5)

20–71

14 (70%)

0.085 (0.009)

29.2 (16.8)

197 (114)

362 (155)

7602 (3001)

Controls with other neurological diseasesb

19

66.5 (8.5)

55–85

10 (53%)

0.093 (0.020)

30.0 (11.6)

234 (87)

4373 (9889)

14,691 (7043)

HC

Healthy controls

20

54.4 (14.5)

23–77

9 (45%)

0.087 (0.010)

30.0 (9.5)

204 (71)

654 (299)

11,751 (6691)

Cohort II

AD

AD asymptomaticc

6

69.0 (13.3)

56–87

2 (33%)

0.054 (0.015)

73.4 (27.3)

468 (115)

n.d.

n.d.

AD MCI

57

67.1 (8.6)

51–82

25 (44%)

0.047 (0.012)

107.7 (36.2)

510 (192)

n.d.

n.d.

AD dementia

42

69.3 (9.4)

51–89

18 (43%)

0.047 (0.013)

130.8 (47.7)

615 (259)

n.d.

n.d.

NeuroDegen

Other neurodegenerative diseases

6

66.5 (11.4)

46–79

2 (33%)

0.118 (0.022)

24.8 (6.4)

211 (31)

n.d.

n.d.

NeuroCtrl

Controls with other neurological diseases

33

58.3 (14.8)

25–84

18 (55%)

0.116 (0.018)

22.7 (8.0)

172 (49)

n.d.

n.d.

HC

Healthy controls

21

58.5 (15.5)

21–85

10 (48%)

0.124 (0.026)

28.7 (12.8)

212 (85)

n.d.

n.d.

  1. aImmune/demyelinating diseases: multiple sclerosis (8), meningitis (3), CNS vasculitis (2), neurosarcoidosis (2), demyelinating polyneuropathy (2), pleocytosis NOS (2), autoimmune encephalopathy (1)
  2. bOther neurological controls: cranial neuropathies (4), vascular (3), headaches (3), normal pressure hydrocephalus (3), polyneuropathy (3), nystagmus (2), essential tremor (1)
  3. cAD asymptomatic: cognitively unimpaired subjects with positive CSF AD biomarkers
  4. dAß42/40 ratio was measured by Quanterix Neuro 4-plex E (cohort I) or Euroimmun beta-amyloid (1-40) and (1-42) ELISA assays (cohort II)
  5. AD Alzheimer’s disease, MCI mild cognitive impairment, NeuroDegen non-AD neurodegenerative diseases, NeuroCtrl other neurological conditions, HC healthy controls, NOS not otherwise specified
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193